Cullinan Associates’s Abbott ABT Stock Holding History

Cullinan Associates’s Portfolio ABT Stock Details ABT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.72M	Sell	26,500 -6,040	-19%	-$682K	0.22%	81
2025 Q4	$4.08M	Sell	32,540 -960	-3%	-$122K	0.28%	72
2025 Q3	$4.49M	Sell	33,500 -594	-2%	-$78K	0.29%	66
2025 Q2	$4.64M	Sell	34,094 -3,000	-8%	-$396K	0.31%	65
2025 Q1	$4.92M	Sell	37,094 -1,900	-5%	-$242K	0.35%	62
2024 Q4	$4.41M	Sell	38,994 -4,800	-11%	-$555K	0.28%	70
2024 Q3	$5.12M	Sell	43,794 -7,700	-15%	-$845K	0.29%	70
2024 Q2	$5.35M	Buy	51,494 +1,000	+2%	+$106K	0.3%	67
2024 Q1	$5.74M	Sell	50,494 -27,586	-35%	-$3.16M	0.32%	66
2023 Q4	$8.59M	Sell	78,080 -18,471	-19%	-$1.85M	0.48%	47
2023 Q3	$9.35M	Sell	96,551 -1,374	-1%	-$144K	0.54%	48
2023 Q2	$10.7M	Sell	97,925 -3,185	-3%	-$340K	0.59%	46
2023 Q1	$10.2M	Sell	101,110 -7,751	-7%	-$818K	0.6%	51
2022 Q4	$12M	Sell	108,861 -5,431	-5%	-$562K	0.66%	34
2022 Q3	$11.1M	Buy	114,292 +1,546	+1%	+$165K	0.7%	40
2022 Q2	$12.3M	Sell	112,746 -8,011	-7%	-$910K	0.75%	38
2022 Q1	$14.3M	Sell	120,757 -542	-0.4%	-$67.2K	0.75%	37
2021 Q4	$17.1M	Buy	121,299 +19,807	+20%	+$2.54M	0.87%	32
2021 Q3	$12M	Buy	101,492 +3,402	+3%	+$418K	0.66%	46
2021 Q2	$11.4M	Buy	98,090 +11,600	+13%	+$1.35M	0.64%	47
2021 Q1	$10.4M	Sell	86,490 -23,950	-22%	-$2.84M	0.6%	44
2020 Q4	$12.1M	Buy	110,440 +8,750	+9%	+$951K	0.73%	29
2020 Q3	$11.1M	Buy	101,690 +2,100	+2%	+$213K	0.71%	28
2020 Q2	$9.11M	Sell	99,590 -555	-0.6%	-$50.2K	0.64%	35
2020 Q1	$7.9M	Buy	100,145 +12,525	+14%	+$1.05M	0.65%	39
2019 Q4	$7.61M	Buy	87,620 +1,455	+2%	+$122K	0.51%	53
2019 Q3	$7.21M	Buy	86,165 +21,935	+34%	+$1.86M	0.51%	53
2019 Q2	$5.4M	Sell	64,230 -1,800	-3%	-$142K	0.39%	72
2019 Q1	$5.28M	Buy	66,030 +14,910	+29%	+$1.11M	0.4%	71
2018 Q4	$3.7M	Buy	51,120 +36,550	+251%	+$2.57M	0.31%	82
2018 Q3	$1.07M	Sell	14,570 -1,200	-8%	-$78.8K	0.08%	128
2018 Q2	$962K	Sell	15,770 -152	-1%	-$9.21K	0.07%	130
2018 Q1	$954K	Sell	15,922 -74,302	-82%	-$4.48M	0.07%	131
2017 Q4	$5.15M	Sell	90,224 -176,774	-66%	-$9.8M	0.38%	75
2017 Q3	$14.2M	Sell	266,998 -12,625	-5%	-$633K	1.1%	16
2017 Q2	$13.6M	Buy	279,623 +457	+0.2%	+$20.7K	1.06%	17
2017 Q1	$12.4M	Sell	279,166 -1,435	-0.5%	-$62K	1.01%	17
2016 Q4	$10.8M	Buy	280,601 +2,301	+0.8%	+$91.2K	0.92%	21
2016 Q3	$11.8M	Sell	278,300 -17,450	-6%	-$748K	1.01%	16
2016 Q2	$11.6M	Sell	295,750 -12,200	-4%	-$486K	0.95%	18
2016 Q1	$12.9M	Buy	307,950 +5,000	+2%	+$198K	1.1%	15
2015 Q4	$13.6M	Buy	302,950 +14,000	+5%	+$618K	1.18%	14
2015 Q3	$11.6M	Buy	288,950 +6,325	+2%	+$298K	1.06%	14
2015 Q2	$13.9M	Sell	282,625 -28,400	-9%	-$1.36M	1.14%	13
2015 Q1	$14.4M	Buy	311,025 +2,157	+0.7%	+$99.1K	1.12%	10
2014 Q4	$13.9M	Buy	308,868 +12,150	+4%	+$529K	1.47%	8
2014 Q3	$12.3M	Buy	296,718 +123,818	+72%	+$5.24M	1.41%	8
2014 Q2	$6.03M	Sell	172,900 -114,586	-40%	-$4.5M	0.98%	9
2014 Q1	$11.1M	Buy	287,486 +23,086	+9%	+$890K	1.26%	10
2013 Q4	$10.1M	Buy	264,400 +39,932	+18%	+$1.47M	1.17%	10
2013 Q3	$7.45M	Buy	224,468 +6,400	+3%	+$225K	1%	15
2013 Q2	$7.61M	Buy	+218,068	New	+$8M	1.03%	12

Other funds holding ABT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cullinan Associates's ABT Position: Q1 2026 in Review

Cullinan Associates reduced its Abbott (ABT) stake by 19% in Q1 2026, selling an estimated $682K and leaving 26,500 shares worth $2.72M. The position accounts for 0.22% of the portfolio, ranked #81.

Cullinan Associates first reported a position in ABT in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.1M in Q4 2021. 3,083 funds tracked by Wall St. Rank hold ABT as of Q1 2026.

Cullinan Associates held 26,500 shares of Abbott worth $2.72M as of Q1 2026.
Cullinan Associates sold 6,040 Abbott shares in Q1 2026, an estimated $682K.
Abbott made up 0.22% of Cullinan Associates's portfolio in Q1 2026, its #81 holding.
Cullinan Associates first reported a position in Abbott in Q2 2013 and has held it in 52 quarters since.
Cullinan Associates's Abbott position peaked at $17.1M in Q4 2021.
3,083 funds tracked by Wall St. Rank held Abbott as of Q1 2026.

Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.